Pharvaris (NASDAQ: PHVS) Soars on Positive HAE Drug Trial Results and Oppenheimer Price Target Hike

• Pharvaris's experimental oral drug, deucrictibant, achieved an 83% reduction in hereditary angioedema (HAE) attack rates in its CHAPTER-3 Phase 3 study.
• Analyst firm Oppenheimer significantly increased its price target for Pharvaris to $75.00 from $50.00, reaffirming an "Outperform" rating.
• The positive clinical trial data and analyst confidence propelled Pharvaris's stock price, reaching a new 52-week high and boosting its market capitalization to approximately $2.64 billion.

Pharvaris (NASDAQ: PHVS) is a late-stage biopharmaceutical company. It focuses on developing new oral drugs for people with hereditary angioedema (HAE). HAE is a genetic condition that causes swelling attacks. The company aims to create treatments that are easier for patients to take than current options.

Analyst firm Oppenheimer is showing increased confidence in Pharvaris. This follows the company's announcement of positive results from a late-stage trial for its experimental oral drug, deucrictibant. As highlighted by Reuters, this drug is designed to prevent swelling attacks in patients with HAE, a rare genetic disorder.

The CHAPTER-3 Phase 3 study for deucrictibant met its main goals. GlobeNewswire reports that the drug showed an 83% reduction in attack rates compared to a placebo. The company plans to apply for marketing approval starting in the first half of 2027 based on this strong data.

Following the positive trial results, Oppenheimer raised its price target for Pharvaris to $75.00 from a previous target of $50.00. The firm also maintained its "Outperform" rating on the stock. This new target suggests significant potential upside from the stock's price of $38.67 at the time of the announcement.

The market reacted positively to the news. The stock price for Pharvaris is currently $37.84, a daily increase of 7.35%. The stock reached a new 52-week high of $43.25 during the day. The company has a market capitalization of approximately $2.64 billion, which is the total value of all its shares.